William Goodnight, MD, MSCR Assistant Professor Division of Maternal Fetal Medicine UNC Chapel Hill School of Medicine.

Slides:



Advertisements
Similar presentations
 may be efective in preventing SGA birth in women at high risk of preeclampsia although the effect size is small. (c)
Advertisements

Preventing Preterm Births: Do Any Screening Tests Help?
 Addition of NEW CPT codes to the service file to code for progesterone supplementation for preterm birth prevention (PTB) in women with specific pregnancy.
Journal Club October 2012 Supervised by Prof.Abdulrahim Rouzi Presented by Dr.Ayman Bukhari.
TEMPLATE DESIGN © Comparison of outcomes of triplet pregnancy with twin pregnancy Kyu-Sang Kyeong, M.D., Jae-Yoon Shim,
Perinatal Health in Canada: An Overview K.S. Joseph MD, PhD Canadian Perinatal Surveillance System.
Preterm is less than 37 completed weeks gestation. Source: National Center for Health Statistics, final natality data. Retrieved May 14, 2014, from
IMPACT OF PREECLAMPSIA ON BIRTH OUTCOMES Xu Xiong, MD, DrPH Department of Obstetrics and Gynecology Université de Montréal, Quebec, Canada.
Infection & Preterm Birth. Objectives Understand magnitude of problem of PTB. Gain understanding of role of infection in spontaneous PTB. Overview of.
Progesteron for Preterm Labour Prevention Prof.Dr.S.Cansun DEM İ R President of FGOM 16.May.2013-Antalya.
Disclosures Dr. Iams has contracts via Ohio State University with: NICHD for clinical research projects OPQC for quality improvement projects Elsevier.
Pretem Labor Ramzy Nakad, MD.
UOG Journal Club: September 2012 Perinatal outcome in women treated with progesterone for the prevention of preterm birth: a meta-analysis Sotiriadis A,
Transvaginal Assessment of the Short and Funneled Cervix Professor Curtis L Lowery MD Department of Ob/Gyn UAMS Collage of Medicine.
Illustration of the evaluation of risk prediction models in randomized trials Examples from women’s health studies Parvin Tajik, MD PhD candidate Department.
Progesterone Therapy for Preterm Labor Perinatal Conference April 14, 2006.
Vaginal Infections and Preterm Birth - An Update J. Chris Carey, MD Disponible en:
Prevention of Recurring Premature Birth Presentation for Health Care Providers June 2008.
Preventing recurrent preterm birth The North Carolina 17P Project Kate Berrien, RN, BSN, MS
Preventing Infant Mortality: What We Know, What We Don’t, and What You Can Do Tom Ivester, MD, MPH UNC School of Medicine Division of Maternal Fetal Medicine.
Meeting of the Advisory Committee for Reproductive Health Drugs August 29, 2006 Barbara Wesley, M.D., M.P.H. Division of Reproductive and Urologic Products.
Cara Pessel, MD et al American Journal of Obstetrics and Gynecology 2013.
Progestogens for Prevention of Preterm Birth Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Predicting and Preventing Preterm Birth
Progesterone for the Prevention of Preterm Birth Paul Meis MD.
Christopher R. Graber, MD Salina Women’s Clinic September 27, 2011 (revised from Mar 2010)
The State of Ohio Universal Prenatal Booking David S. McKenna, MD, RDMS Maternal-Fetal Medicine Miami Valley Hospital, Dayton OH.
Healthy Pregnancy Monica Riccomini, RN, MSN Lisa Lottritz RN, BSN.
Institute of Medicine Research Issues in the Assessment of Birth Settings: Assessment of Risk in Pregnancy Discussant M. Kathryn Menard, MD MPH Professor.
CityMatCH / NACCHO Emerging Issues in Maternal and Child Health Conference Call Impact of Healthy Weight in Mothers on Birth Outcomes August 19, 2004 Siobhan.
I. Hospital admissions II. Intervention result in relation to FFN III. Gestational age In relation to FFN IV. In relation to delivery V. Relation of delivery.
In the name of God.
The Post-Partum Visit Re-Design Jeanne A. Conry, MD, PhD Chair, ACOG District IX.
Vaginal Birth After Cesarean: Is it Still an Option
Pr MEDJTOH DR BENLAHARCHE
Progesterone…We can prevent some prematurity if we try
Preterm Birth Present by: Dr.Worapa Asavaritikrai Health Promotion Center Region 4.
Preterm Delivery: An Update on Prevention and Treatment Tara Lehman, MD MPH CCRMC June 3, 2009.
Preterm labor.
Christopher R. Graber, MD Salina Women’s Clinic Mar 3, 2010.
Class 15, 1st year Introdução à Medicina II 28th May 2010
Preterm Birth Hazem Al-Mandeel, M.D Course 481 Obstetrics and Gynecology Rotation.
Laleh Eslamian MD, Prof of Obstet& Gynecol, Perinatologist, TUMS.
CMV +ve Control Introduction cCMV affects ~1% of all newborns born annually in the U.S. ~ 10% born with symptoms typically associated with cCMV Most develop.
Preterm Labor & Preterm Birth Family Medicine Specialist CME Vientiane, Lao PDR December 10 – 12, 2008.
UOG Journal Club: July 2011 Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized,
Preterm Labor Williams CH.36. Preterm Birth Death, severe neonatal morbidities Common before 26 weeks Universal before 24 weeks.
Cervical length & Prediction of preterm labor Current Opinion in Obstetrics & Gynecology 19, April 2007 p.191~195 부산백병원 산부인과 R2 정은정.
MANAGEMENT OF PRETERM LABOR WITH INTACT MEMBRANES by Dr. Elmizadeh.
Progesterone & Prevention of Preterm Delivery
Explaining the Infant Mortality Increase Marian MacDorman, Joyce Martin, T.J.Mathews, Donna Hoyert, and Stephanie Ventura Division of Vital Statistics.
Prenatal Progesterone for Preventing Preterm Birth.
Roger B. Newman, MD Professor and Maas Chair for Reproductive Sciences
UOG Journal Club: March 2017
Infection & Preterm Birth
Critical review of interventions to reduce risk of preterm birth
ROLE OF PROGESTERONE IN PREGNANCY MAINTENANCE & LATER IN PREGNANCY
UOG Journal Club: March 2017
Evidence based management of preterm labour
The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial SHERIF ASHOUSH1, OSAMA.
Perinatal Quality Foundation (
Alexander Ansah Manu (BSc MD MSc PhD DLSHTM)
Operationalizing Inclusion
17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study David B. Nelson, MD; Donald D. McIntire,
Alexander Ansah Manu (BSc MD MSc PhD DLSHTM)
Welcome West Virginia Perinatal Partnership
Win Nanda Myo, Khin May Htwe, San San Myint
Chantal Nelson BORN Annual Conference April 25, 2017
Presentation transcript:

William Goodnight, MD, MSCR Assistant Professor Division of Maternal Fetal Medicine UNC Chapel Hill School of Medicine

Scope of the problem - US  Preterm Birth – delivery <37 weeks EGA National Center for Health Statistics. Retrieved October 15, 2009, from

Scope of the Problem - NC National Center for Health Statistics. Retrieved October 15, 2009, from

Scope of the Problem - NC National Center for Health Statistics. Retrieved October 15, 2009, from

Implications of PTB  Leading cause neonatal morbidity and mortality long term morbidity ○ cerebral palsy ○ developmental delay

Risk factors for preterm birth  Prior PTB ***  Multiple gestation  Short cervical length  Low maternal BMI  African American  Maternal age  Smoking

Interventions to prevent PTB  Prenatal care Social support  Lifestyle changes Smoking cessation Improved nutrition  Cerclage  Infections  Home uterine activity monitoring  Tocolytic medications Trials of acute care of PTL show little benefit in prevention of PTB

Progesterone for prevention of PTB  Small trials in 1970’s and 80’s  Suggested Reduction in preterm birth  Variable dosing IM Vaginal  Variable populations

Early progesterone trials  5 trials in high risk women with 17P vs. placebo  Overall risks of: preterm birth ○ OR 0.50, 95% CI: low birth weight ○ OR 0.46, 95% CI:  No difference in morbidity/mortality Keirse MJNC. Brit J Obstet Gynecol 1990;97:149

Why may progesterone work?  Functional prog withdrawal stimulates labor Increase PR-A/PR-B expression Decrease progesterone receptors  Progesterone as anti-inflammatory  Reduce myometrial gap junctions Decrease conduction of contractions  Reduces threshold for contractions

NICHD/MFMU 17 α-Hydroxyprogesterone Caproate New England Journal of Medicine, 2003; 348 (24)

17P – NICHD (Meis, 2003, NEJM) N=463 Prior preterm birth 20 – 36 6/7 wks SPTB, PPROM N = P 250mg IM weekly 16-20wks – 36wks N= 153 Placebo Primary outcome: PTB < 37 weeks EGA

17-P NICHD trial (Meis, 2003, NEJM)  Study population 17 PPlacebo GA prior PTB30.6 wk31.3 wk # prior PTB * Married51.3%46.4% BMI > 1 prior PTB27.7%41.2% Non-Hispanic Black59.0%58.8% GA at randomization18.4 wk * p<0.007

17P – NICHD (Meis, 2003, NEJM) PTB rates

p < 0.05

17P – NICHD (Meis, 2003, NEJM) Neonatal morbidity * p < 0.05

17P – NICHD (Meis, 2003, NEJM)  Summary  Weekly 17P ○ 34% reduction in PTB < 37 weeks ○ 33% reduction in PTB < 35 weeks ○ 42% reduction in PTB < 32 weeks  Number need to treat 5-6 (95% CI 3.6, 11) for prevention of 1 PTB < (95% CI 6.3, 74.6) for PTB < 32

17 – P: Safety  Rebarber, 2007, Diabetes Care 17-P associated with 3 x increased risk of GDM (95% CI 2.1,4.1) ○ 12.9% vs. 4.9%  4 year outcome of exposed children No congenital anomalies Normal neurological development Northern AT, Norman GS, Anderson K, et al. Obstet Gynecol 2007;110:865–872.

17 –P side effects  Meis, 2003 NEJM – injection site s/s Symptom% Soreness34.2 Swelling14.1 Itching11.3 Bruising6.7

Cost effective  Obido, et al (2006) Obstetrics and Gynecology Modeled 17P costs vs. costs of PTB  17P cost effective Prevention of PTB ○ Prior preterm birth <32 weeks ○ Prior preterm birth weeks

17 P costs/savings  Modeled costs of 17 P and PTB  Use of 17 P with prior SPTB Savings ○ $3800 per woman treated ○ $15,900 per infant treated Total - $2 billion annual savings Bailit JL, Votruba ME.. Am J Obstet Gynecol

Use of 17 P among MFM physicians  Ness, 2006 AJOG, survey

17 – P twins and triplets  High risk populations  NICHD trials of 17P vs. placebo  Twins – no difference in PTB No difference in morbidity  Triplets – no difference in PTB Rouse, NEJM, 2007 Caritis, Obstet Gynecol 2009

Other progesterone trials  O’Brien, Ultrasound Ob/Gyn, 2007 Vaginal progesterone gel, similar population 90 mg progesterone (Crinone®) No difference in PTB < 32 weeks  deFonseca, Am J Obstet Gyneol, mg micronized vaginal progesterone reduction in PTB <34 weeks in progesterone group (2.7% vs. 18.6%)

Other progesterone trials  Fonseca, NEJM, 2007 Cervical length at 22 weeks <15mm 200mg micronized vaginal progesterone 44% reduction in PTB <34 weeks in progesterone group (19% vs. 34.4%)

 Recommended Prevention of recurrent PTB ○ Current singleton pregnancy ○ Prior preterm birth due to SPTL, PPROM weeks EGA  Considered Asymptomatic short cervix (<15mm) Routine screening not recommended How to give it o 17 alpha OHP – 250 mg IM weekly o Start weeks EGA o Continue to completed 36 th week o Ok to use in diabetes ACOG/SMFM Recommendations Obstetrics and Gynecology, Vol 112(4), 2008

ACOG/SMFM Recommendations  Not recommended Tocolytic Supplement to cerclage + FFN in asymptomatic patient Therapeutic agent after tocolysis Multiple gestations Obstetrics and Gynecology, Vol 112(4), 2008

Questions or to discuss if a patient is a 17 P candidate: